Glanbia plc is holding a ‘Capital Markets Day’ (CMD) today (Wednesday, November 19), which will focus on the business’ growth strategy and associated financial targets from 2026 to 2028.
Glanbia’s financial metrics for the 2026 to 2028 financial years will be outlined at the CMD.
These include growth in adjusted earnings per share (EPS) of 7% to 11%, and operating cash conversion of EBITDA (earnings before interest, taxes, depreciation and amortisation) of 85%.
The business is also targeting a return on capital employed of 10% to 13%, as well as a target dividend payout ratio of between 30% and 40%.
Glanbia business
By business segment, the company is aiming to see annual organic revenue growth in the Performance Nutrition business of 5% to 7%.
Glanbia also wants to see total three-year EBITDA margin progression in Performance Nutrition of 250 basis points (2.5%) from the reported base in full year 2025 (FY25).
In the Health and Nutrition business, the company is targeting organic revenue growth of 4% to 6% and an EBITDA margin range of 17% to 19%.
In the Dairy Nutrition business, Glanbia is targeting an annual EBITDA range of approximately $150 million to $160 million.
The Capital Markets Day will be held at the London Stock Exchange and will run from 2:00p.m to around 4:30p.m. The event will be broadcast live via a webcast.
Commenting on the Capital Markets Day and the business’ targets for the coming years, Hugh McGuire, CEO of Glanbia, said: “Glanbia sits at the centre of powerful consumer megatrends, focused on fast-growing health and wellness categories.
“Through our portfolio of leading brands and ingredients, we help consumers around the world to achieve their health, fitness and nutrition goals,” McGuire added.
“Today’s event will showcase how we are sharpening our focus to achieve our three-year growth ambition and capitalise on the significant opportunities ahead.
"We are well positioned to deliver on our ambition to drive growth and shareholder returns,” the CEO commented.
